(MENAFN- Market Press Release) October 12, 2025 11:13 pm - The Anti-inflammatory Drugs for Cystic Fibrosis Market, valued at USD 2.35 billion in 2025, is forecast to reach USD 3.5 billion by 2032 at a 6% CAGR.

Anti-inflammatory Drugs for Cystic Fibrosis Market Set to Reach USD 3.5 Billion by 2032, Driven by Advancements in Targeted Therapies and Rising Diagnosis Rates

The global Anti-inflammatory Drugs for Cystic Fibrosis Market, valued at USD 2,350 million in 2025, is projected to reach approximately USD 3,500 million by 2032, registering a CAGR of 6% during the forecast period. Rising investments in pulmonary care drugs, growth in personalized medicine, and the increasing prevalence of cystic fibrosis, especially in North America and Europe, are fueling market expansion. Additionally, regulatory support and faster drug approvals by agencies such as the FDA and EMA are creating a favorable environment for innovation and commercial adoption.

Key Segment or Application Focus

Hospital pharmacies, specialty clinics, and home care settings remain the primary channels for anti-inflammatory drug administration. Among drug classes, corticosteroids and NSAIDs hold significant market share due to their wide acceptance in managing chronic lung inflammation. Emerging biologics targeting neutrophil-driven inflammation are gaining traction, particularly in advanced-stage cystic fibrosis treatment protocols, signaling a shift toward high-value precision therapy solutions.

Price Trend

In 2024, the average treatment cost per patient in the United States ranged between USD 9,200–9,500 annually, while in Germany, prices were slightly lower at USD 8,700 due to stronger reimbursement frameworks. By 2025, U.S. prices are expected to rise by 3–4%, driven by R&D-associated premium pricing for biologics. In contrast, United Kingdom pricing remains relatively stable, supported by government-negotiated contracts under NHS procurement, mitigating cost escalation for patients.

Key Players Snapshot

North America is dominated by pharmaceutical leaders such as Vertex Pharmaceuticals and AbbVie, both actively expanding their anti-inflammatory cystic fibrosis pipelines. In Europe, companies like Roche and Novartis are accelerating clinical trials to enhance their portfolio competitiveness. Meanwhile, Asia-Pacific players including Sun Pharma and Cipla are focusing on affordable formulations and expanding distribution networks to capture emerging market demand, particularly in India and Southeast Asia.

Request for customization

MENAFN13102025003520003262ID1110186304